| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | structural constituent of muscle | 1.26e-04 | 43 | 8 | 2 | GO:0008307 | |
| GeneOntologyBiologicalProcess | sarcomere organization | 1.67e-04 | 59 | 7 | 2 | GO:0045214 | |
| GeneOntologyBiologicalProcess | myofibril assembly | 3.56e-04 | 86 | 7 | 2 | GO:0030239 | |
| GeneOntologyBiologicalProcess | striated muscle cell development | 3.81e-04 | 89 | 7 | 2 | GO:0055002 | |
| GeneOntologyBiologicalProcess | cellular component assembly involved in morphogenesis | 1.16e-03 | 156 | 7 | 2 | GO:0010927 | |
| GeneOntologyBiologicalProcess | cellular anatomical entity morphogenesis | 1.16e-03 | 156 | 7 | 2 | GO:0032989 | |
| GeneOntologyBiologicalProcess | protein modification by small protein conjugation | 2.48e-03 | 893 | 7 | 3 | GO:0032446 | |
| GeneOntologyBiologicalProcess | actomyosin structure organization | 2.70e-03 | 239 | 7 | 2 | GO:0031032 | |
| GeneOntologyBiologicalProcess | muscle cell development | 3.16e-03 | 259 | 7 | 2 | GO:0055001 | |
| GeneOntologyBiologicalProcess | regulation of protein modification by small protein conjugation or removal | 3.46e-03 | 271 | 7 | 2 | GO:1903320 | |
| GeneOntologyBiologicalProcess | protein modification by small protein conjugation or removal | 3.52e-03 | 1009 | 7 | 3 | GO:0070647 | |
| GeneOntologyBiologicalProcess | regulation of post-translational protein modification | 3.61e-03 | 277 | 7 | 2 | GO:1901873 | |
| GeneOntologyBiologicalProcess | post-translational protein modification | 4.21e-03 | 1074 | 7 | 3 | GO:0043687 | |
| GeneOntologyCellularComponent | Z disc | 1.41e-03 | 151 | 8 | 2 | GO:0030018 | |
| GeneOntologyCellularComponent | I band | 1.70e-03 | 166 | 8 | 2 | GO:0031674 | |
| GeneOntologyCellularComponent | sarcomere | 3.77e-03 | 249 | 8 | 2 | GO:0030017 | |
| GeneOntologyCellularComponent | myofibril | 4.52e-03 | 273 | 8 | 2 | GO:0030016 | |
| GeneOntologyCellularComponent | contractile muscle fiber | 5.08e-03 | 290 | 8 | 2 | GO:0043292 | |
| MousePheno | abnormal A band morphology | 1.29e-05 | 10 | 8 | 2 | MP:0030566 | |
| MousePheno | decreased skeletal muscle fiber diameter | 2.44e-04 | 42 | 8 | 2 | MP:0009402 | |
| Domain | SAM_1 | 3.61e-04 | 68 | 8 | 2 | PF00536 | |
| Domain | SAM | 6.03e-04 | 88 | 8 | 2 | SM00454 | |
| Domain | SAM_DOMAIN | 7.03e-04 | 95 | 8 | 2 | PS50105 | |
| Domain | SAM | 7.32e-04 | 97 | 8 | 2 | IPR001660 | |
| Domain | - | 8.74e-04 | 106 | 8 | 2 | 1.10.150.50 | |
| Domain | SAM/pointed | 1.06e-03 | 117 | 8 | 2 | IPR013761 | |
| Domain | SH3 | 3.56e-03 | 216 | 8 | 2 | PS50002 | |
| Domain | SH3 | 3.56e-03 | 216 | 8 | 2 | SM00326 | |
| Domain | SH3_domain | 3.69e-03 | 220 | 8 | 2 | IPR001452 | |
| Domain | PH | 5.83e-03 | 278 | 8 | 2 | SM00233 | |
| Domain | PH_DOMAIN | 5.87e-03 | 279 | 8 | 2 | PS50003 | |
| Domain | PH_domain | 5.91e-03 | 280 | 8 | 2 | IPR001849 | |
| Domain | PH_dom-like | 1.33e-02 | 426 | 8 | 2 | IPR011993 | |
| GeneFamily | Sterile alpha motif domain containing | 1.40e-04 | 88 | 4 | 2 | 760 | |
| Coexpression | GSE41176_UNSTIM_VS_ANTI_IGM_STIM_TAK1_KO_BCELL_1H_DN | 2.38e-05 | 200 | 8 | 3 | M9928 | |
| Coexpression | ZHOU_INFLAMMATORY_RESPONSE_FIMA_DN | 6.42e-05 | 279 | 8 | 3 | M250 | |
| ToppCell | COVID-19-Heart-Fib_+_CM|Heart / Disease (COVID-19 only), tissue and cell type | 1.47e-04 | 104 | 8 | 2 | 0b60a56a46f1fe3f8224ec6399d009a34a117a21 | |
| ToppCell | COVID-19-Heart-Fib_+_CM|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.70e-04 | 112 | 8 | 2 | d00ee6b19e41a35450681fe676885983536d6292 | |
| ToppCell | TCGA-Uterus-Primary_Tumor-Uterine_Carcinoma-Uterine_Carcinosarcoma-4|TCGA-Uterus / Sample_Type by Project: Shred V9 | 2.33e-04 | 131 | 8 | 2 | 1801611e6b63aa07629e7ccc692f45a7e93c8dd8 | |
| ToppCell | AT1-AT2_cells-Donor_08|World / lung cells shred on cell class, cell subclass, sample id | 2.85e-04 | 145 | 8 | 2 | cd5de30fd948024e3ad043c9411ce9f2722178b2 | |
| ToppCell | Control-PLT_4|World / Disease Group and Platelet Clusters | 3.22e-04 | 154 | 8 | 2 | a2a03c5e6759c45aeeedf1e68ecb5a0112ef9a20 | |
| ToppCell | 10x5'-Lung-Lymphocytic_T_CD4-Tnaive/CM_CD4_activated|Lung / Manually curated celltypes from each tissue | 3.47e-04 | 160 | 8 | 2 | 9f7f24a52a24fb926df69c8e5aad64ee75a66ef1 | |
| ToppCell | 390C-Myeloid-Dendritic-cDC_proliferating_2|Dendritic / Donor, Lineage, Cell class and subclass (all cells) | 3.56e-04 | 162 | 8 | 2 | a957c7e347189b72fbd47db3075bb5e879a21c67 | |
| ToppCell | 5'-Adult-Appendix-Hematopoietic-Plasma_cells-IgG_plasma_cell|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 3.69e-04 | 165 | 8 | 2 | 79c6ad394266ff092029375883660028e944a3c8 | |
| ToppCell | droplet-Lung-nan-3m-Lymphocytic-Regulatory_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.82e-04 | 168 | 8 | 2 | 1df3c8c7a6dceb901805eaba7f86f9943f4f1a9d | |
| ToppCell | droplet-Lung-nan-3m-Lymphocytic-regulatory_T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.82e-04 | 168 | 8 | 2 | 1586451d437b70b2dffe41d782b694702dcaf50b | |
| ToppCell | facs-Marrow-T-cells-3m-Lymphocytic-BM_CD4_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.96e-04 | 171 | 8 | 2 | f4cdd7862c8fe99ee765a2f3ed375b584f4976c5 | |
| ToppCell | facs-Marrow-T-cells-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.96e-04 | 171 | 8 | 2 | 8719a18c9e6b6f5d8ec4e937c2bda1e36441c9ec | |
| ToppCell | droplet-Limb_Muscle-Pre-Sort-18m-Mesenchymal-skeletal_muscle_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.10e-04 | 174 | 8 | 2 | 4a6e04b4f12b87c15fa1409989cbe32c43736369 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-Plasma_B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 4.20e-04 | 176 | 8 | 2 | 125be81311f87563ca321472fcce6e0e0ae24c16 | |
| ToppCell | 10x_3'_v2v3-Non-neoplastic-Lymphoid-Plasma_B-Plasma_B|10x_3'_v2v3 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 4.20e-04 | 176 | 8 | 2 | 67d6dc38708692f8c58cea5ed896f10718e9ffa6 | |
| ToppCell | droplet-Kidney-KIDNEY-1m-Lymphocytic-T_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.24e-04 | 177 | 8 | 2 | 36da06ca9577cdb7c7b5114e604f6546b9765c08 | |
| ToppCell | droplet-Limb_Muscle-nan-21m-Mesenchymal-skeletal_muscle_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.39e-04 | 180 | 8 | 2 | cea62fc006d68c3815c88bf17ec2617d7e41c3d2 | |
| ToppCell | droplet-Limb_Muscle-nan-3m-Mesenchymal-skeletal_muscle_cell|Limb_Muscle / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.48e-04 | 182 | 8 | 2 | edfc598b7199ca1d8a399b264ab863c299b1eede | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 184 | 8 | 2 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 184 | 8 | 2 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 184 | 8 | 2 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | droplet-Kidney-KIDNEY-1m-Lymphocytic-CD45____T_cell|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 4.58e-04 | 184 | 8 | 2 | 2c8e9ddce3e60302965dcf9dee77c4fe33e4071d | |
| ToppCell | COVID-19_Convalescent-PLT_4|World / Disease Group and Platelet Clusters | 4.68e-04 | 186 | 8 | 2 | 5954a1e3ffafb33f2a9bc87af3343f304fda4c92 | |
| ToppCell | renal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Degenerative_Proximal_Tubule_Epithelial_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 4.73e-04 | 187 | 8 | 2 | 3ae3b8de1a195d4d5057cf3c64fcdb5f48681ce5 | |
| ToppCell | LV-10._Endothelium_II|World / Chamber and Cluster_Paper | 4.73e-04 | 187 | 8 | 2 | 7876dcb4800c2e54874df3d933efb79307a64a97 | |
| ToppCell | RA-10._Endothelium_II|World / Chamber and Cluster_Paper | 4.83e-04 | 189 | 8 | 2 | 75c248b9de5e2fb7a0baa8cdbab516e575cc4394 | |
| ToppCell | Control|World / Disease state, Lineage and Cell class | 4.83e-04 | 189 | 8 | 2 | fb8dddd3b901081c6bb9ed6f32dafc5cce5f30be | |
| ToppCell | RA-10._Endothelium_II|RA / Chamber and Cluster_Paper | 4.83e-04 | 189 | 8 | 2 | c81787a8c662db5d7814c583dd64562857629e81 | |
| ToppCell | Primary_Motor_Cortex_(M1)-Non-neuronal-Macroglial|Primary_Motor_Cortex_(M1) / Sample groups (6 Anatomical region groups), with 5 level hierarchy of cell types | 4.89e-04 | 190 | 8 | 2 | ae97df1b06bcd46c05759b53c35dc8fea97f4ac1 | |
| ToppCell | RV-10._Endothelium_II|World / Chamber and Cluster_Paper | 5.04e-04 | 193 | 8 | 2 | 2531266bc57339d4e2b22a88817008e32b8c1598 | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Mesenchymal|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type. | 5.04e-04 | 193 | 8 | 2 | e1de67ddada87229f5db0ec193a6da8745a86a64 | |
| ToppCell | RV-10._Endothelium_II|RV / Chamber and Cluster_Paper | 5.04e-04 | 193 | 8 | 2 | 01c2df9206f1527c578e808978e58196c35e72f5 | |
| ToppCell | Brain_organoid-organoid_Kanton_Nature-Organoid-1M-Mesenchymal-choroid_plexus/mesenchymal-like_cells|Organoid-1M / Sample Type, Dataset, Time_group, and Cell type. | 5.04e-04 | 193 | 8 | 2 | b6f5a85210e60798205eaf5884cdb540f549d08a | |
| ToppCell | LV-10._Endothelium_II|LV / Chamber and Cluster_Paper | 5.09e-04 | 194 | 8 | 2 | b6cc849fa08599bff9839ef382d190cc964e273e | |
| ToppCell | Control-PLT_1|Control / Disease Group and Platelet Clusters | 5.14e-04 | 195 | 8 | 2 | 20ee45983a5675d9fa072d02dd45c6ce8662d7d7 | |
| ToppCell | facs-Aorta-Heart-3m-Endothelial-aorta_endothelial_cell|Aorta / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 5.14e-04 | 195 | 8 | 2 | 3969b8d5fcec8ef1831531a781f7bbcebab5a4ba | |
| ToppCell | Bronchial-NucSeq-Immune_Lymphocytic-B-B_cell-B_naive|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations | 5.20e-04 | 196 | 8 | 2 | de43dd0697e1daf4d50800957cf0b27b54a7a333 | |
| ToppCell | Transverse-(5)_Dendritic_cell-(53)_Lymphoid_DC|Transverse / shred on region, Cell_type, and subtype | 5.25e-04 | 197 | 8 | 2 | 15b87fd3906d7388c271d30d0c64b1bcc490801c | |
| ToppCell | Transverse-Dendritic_cell-Lymphoid_DC|Dendritic_cell / Region, Cell class and subclass | 5.25e-04 | 197 | 8 | 2 | 8545baf923ddf84c5ce9414a36d810603be52401 | |
| ToppCell | Tracheal-10x3prime_v2-Epithelial-Epi_airway_neuro-secretory|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations | 5.25e-04 | 197 | 8 | 2 | ff4df77117165b6b25315e29b0722cc136eba607 | |
| ToppCell | Transverse-Dendritic_cell-Lymphoid_DC|Transverse / Region, Cell class and subclass | 5.25e-04 | 197 | 8 | 2 | a58af0ea82f76f2a7abac1f62629ff20d552fc63 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.36e-04 | 199 | 8 | 2 | 1bb5797e8e0552bf9b44bf4c958d1aa6dbe6c756 | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.36e-04 | 199 | 8 | 2 | 5d2e85e40b6b52b1809e680b952913d77215b3d0 | |
| ToppCell | Bronchial-10x5prime-Stromal-Peri/Epineurial_|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 5.36e-04 | 199 | 8 | 2 | 45c3b853900d8c3d5965117d904e3714100138bc | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.36e-04 | 199 | 8 | 2 | 9dd4b17fb8c70ab9e126b23b72600463f3db832d | |
| ToppCell | 10x_5'_v1-Non-neoplastic-Glial-Neuronal-Oligodendrocyte-Oligodendrocyte-Z|10x_5'_v1 / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 5.36e-04 | 199 | 8 | 2 | 6fb5f931e6217142de38c1fffc011e63bda4772b | |
| ToppCell | Brain_organoid-organoid_Tanaka_cellReport-3m-Mesenchymal-Mesoderm|3m / Sample Type, Dataset, Time_group, and Cell type. | 5.41e-04 | 200 | 8 | 2 | 538ae964db58c4acafe93f735b3e03fc08fdaac6 | |
| Drug | Urapidil hydrochloride [64887-14-5]; Down 200; 9.4uM; HL60; HT_HG-U133A | 3.62e-05 | 200 | 8 | 3 | 3078_DN | |
| Drug | AC1NR9O8 | 1.42e-04 | 52 | 8 | 2 | CID005287428 | |
| Drug | Air Pollutants | 1.61e-04 | 917 | 8 | 4 | ctd:D000393 | |
| Drug | AC1L1GT5 | 4.75e-04 | 95 | 8 | 2 | CID000003829 | |
| Drug | methyl 9-octadecenoate | 6.59e-04 | 112 | 8 | 2 | CID000008202 | |
| Drug | Hexetidine [141-94-6]; Up 200; 11.8uM; MCF7; HT_HG-U133A | 1.52e-03 | 171 | 8 | 2 | 3318_UP | |
| Drug | LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A_EA | 1.58e-03 | 174 | 8 | 2 | 1019_UP | |
| Drug | (-)-Isoproterenol hydrochloride [5984-95-2]; Down 200; 16.2uM; HL60; HT_HG-U133A | 1.90e-03 | 191 | 8 | 2 | 6149_DN | |
| Drug | Methionine sulfoximine (L) [15985-39-4]; Up 200; 22.2uM; MCF7; HT_HG-U133A | 1.92e-03 | 192 | 8 | 2 | 4151_UP | |
| Drug | Estropipate [7280-37-7]; Down 200; 9.2uM; MCF7; HT_HG-U133A | 1.92e-03 | 192 | 8 | 2 | 6808_DN | |
| Drug | Cyclosporin A [59865-13-3]; Down 200; 3.4uM; HL60; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 1331_DN | |
| Drug | Retrorsine [480-54-6]; Down 200; 11.4uM; HL60; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 2129_DN | |
| Drug | Succinylsulfathiazole [116-43-8]; Down 200; 11.2uM; HL60; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 2166_DN | |
| Drug | Tolazamide [1156-19-0]; Up 200; 12.8uM; HL60; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 2482_UP | |
| Drug | LY 294002; Up 200; 10uM; MCF7; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 1652_UP | |
| Drug | Fenoprofen calcium salt dihydrate [53746-45-5]; Down 200; 7.2uM; MCF7; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 3412_DN | |
| Drug | Fluoxetine hydrochloride [59333-67-4]; Up 200; 11.6uM; PC3; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 6757_UP | |
| Drug | (d,l)-Tetrahydroberberine [522-97-4]; Down 200; 11.8uM; MCF7; HT_HG-U133A | 1.94e-03 | 193 | 8 | 2 | 4138_DN | |
| Drug | Zomepirac sodium salt [64092-48-4]; Down 200; 12.8uM; MCF7; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 3454_DN | |
| Drug | Nafronyl oxalate [3200-06-4]; Up 200; 8.4uM; HL60; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 1267_UP | |
| Drug | Oxyphenbutazone [129-20-4]; Down 200; 12.4uM; HL60; HT_HG-U133A | 1.96e-03 | 194 | 8 | 2 | 6160_DN | |
| Drug | CP-320650-01 [172079-28-6]; Up 200; 1uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 4382_UP | |
| Drug | Pentoxifylline [6493-05-6]; Down 200; 14.4uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 2290_DN | |
| Drug | Bumetanide [28395-03-1]; Down 200; 11uM; HL60; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 2409_DN | |
| Drug | Acacetin [480-44-4]; Up 200; 14uM; HL60; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 2189_UP | |
| Drug | Thiocolchicoside [602-41-5]; Down 200; 7uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 5520_DN | |
| Drug | 5252917; Down 200; 14uM; MCF7; HT_HG-U133A_EA | 1.98e-03 | 195 | 8 | 2 | 944_DN | |
| Drug | 17-AAG; Up 200; 1uM; MCF7; HT_HG-U133A | 1.98e-03 | 195 | 8 | 2 | 1650_UP | |
| Drug | Lithocholic acid [434-13-9]; Down 200; 10.6uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 2571_DN | |
| Drug | alpha-estradiol; Up 200; 0.01uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 1151_UP | |
| Drug | ICI182,780; Up 200; 1uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 5926_UP | |
| Drug | Methiazole; Up 200; 15uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 3796_UP | |
| Drug | Evoxine [522-11-2]; Down 200; 11.6uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 2186_DN | |
| Drug | Fluvastatin sodium salt [93957-55-2]; Down 200; 9.2uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 3032_DN | |
| Drug | Bromopride [4093-35-0]; Up 200; 11.6uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4741_UP | |
| Drug | Felbinac [5728-52-9]; Down 200; 18.8uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 5700_DN | |
| Drug | Methimazole [60-56-0]; Up 200; 35uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4372_UP | |
| Drug | Moricizine hydrochloride [31883-05-3]; Up 200; 8.6uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 6000_UP | |
| Drug | Isopropamide iodide [71-81-8]; Up 200; 8.4uM; MCF7; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 6781_UP | |
| Drug | Epitiostanol [2363-58-8]; Down 200; 13uM; HL60; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 2922_DN | |
| Drug | Metrizamide [31112-62-6]; Up 200; 5uM; PC3; HT_HG-U133A | 2.00e-03 | 196 | 8 | 2 | 4075_UP | |
| Drug | Canavanine sulfate monohydrate (L,+) [206996-57-8]; Down 200; 13.6uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 2141_DN | |
| Drug | Viomycin sulfate [37883-00-4]; Down 200; 5.2uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 2979_DN | |
| Drug | Ioversol [87771-40-2]; Up 200; 5uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 6726_UP | |
| Drug | Desipramine hydrochloride [58-28-6]; Down 200; 13.2uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 5292_DN | |
| Drug | Midecamycin [35457-80-8]; Down 200; 5uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 1526_DN | |
| Drug | 3-Acetylcoumarin [3949-36-8]; Down 200; 21.2uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3044_DN | |
| Drug | Harmalol hydrochloride dihydrate [6028-07-5]; Up 200; 14.6uM; PC3; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 5076_UP | |
| Drug | 3-alpha-Hydroxy-5-beta-androstan-17-one [53-42-9]; Down 200; 13.8uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3639_DN | |
| Drug | Equilin [474-86-2]; Down 200; 15uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3039_DN | |
| Drug | 5707885; Down 200; 50uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 6385_DN | |
| Drug | Monensin sodium salt [22373-78-0]; Down 200; 5.8uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 3443_DN | |
| Drug | 0179445-0000 [211246-22-9]; Up 200; 1uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 4758_UP | |
| Drug | Glycopyrrolate [596-51-0]; Down 200; 10uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 2565_DN | |
| Drug | Sulindac [38194-50-2]; Up 200; 11.2uM; MCF7; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 5528_UP | |
| Drug | Atractyloside potassium salt [102130-43-8]; Down 200; 5uM; HL60; HT_HG-U133A | 2.02e-03 | 197 | 8 | 2 | 2573_DN | |
| Drug | Triprolidine hydrochloride [550-70-9]; Up 200; 12.8uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 7008_UP | |
| Drug | Solasodine [126-17-0]; Up 200; 9.6uM; MCF7; HT_HG-U133A | 2.04e-03 | 198 | 8 | 2 | 6025_UP | |
| Disease | unipolar depression, alcohol dependence | 1.91e-04 | 78 | 8 | 2 | EFO_0003761, MONDO_0007079 | |
| Disease | triglyceride measurement, alcohol drinking | 3.08e-04 | 99 | 8 | 2 | EFO_0004329, EFO_0004530 | |
| Disease | triglyceride measurement, alcohol consumption measurement | 3.20e-04 | 101 | 8 | 2 | EFO_0004530, EFO_0007878 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement | 3.53e-04 | 106 | 8 | 2 | EFO_0008317, EFO_0008596 | |
| Disease | chylomicron measurement, very low density lipoprotein cholesterol measurement, phospholipid measurement | 3.73e-04 | 109 | 8 | 2 | EFO_0004639, EFO_0008317, EFO_0008596 | |
| Disease | free cholesterol measurement, chylomicron measurement, very low density lipoprotein cholesterol measurement | 3.80e-04 | 110 | 8 | 2 | EFO_0008317, EFO_0008591, EFO_0008596 | |
| Disease | chylomicron measurement, total cholesterol measurement, very low density lipoprotein cholesterol measurement | 3.80e-04 | 110 | 8 | 2 | EFO_0004574, EFO_0008317, EFO_0008596 | |
| Disease | sleep duration, high density lipoprotein cholesterol measurement | 4.59e-04 | 121 | 8 | 2 | EFO_0004612, EFO_0005271 | |
| Disease | pursuit maintenance gain measurement | 4.75e-04 | 123 | 8 | 2 | EFO_0008433 | |
| Disease | language measurement | 5.63e-04 | 134 | 8 | 2 | EFO_0007797 | |
| Disease | triglyceride measurement, phospholipid measurement | 6.68e-04 | 146 | 8 | 2 | EFO_0004530, EFO_0004639 | |
| Disease | triglycerides:total lipids ratio, low density lipoprotein cholesterol measurement | 7.04e-04 | 150 | 8 | 2 | EFO_0004611, EFO_0020947 | |
| Disease | alcohol consumption measurement, high density lipoprotein cholesterol measurement | 8.21e-04 | 162 | 8 | 2 | EFO_0004612, EFO_0007878 | |
| Disease | triglyceride measurement, low density lipoprotein cholesterol measurement | 8.61e-04 | 166 | 8 | 2 | EFO_0004530, EFO_0004611 | |
| Disease | reading and spelling ability | 8.61e-04 | 166 | 8 | 2 | EFO_0005301 | |
| Disease | alcohol drinking, high density lipoprotein cholesterol measurement | 8.82e-04 | 168 | 8 | 2 | EFO_0004329, EFO_0004612 | |
| Disease | mean reticulocyte volume | 1.00e-03 | 799 | 8 | 3 | EFO_0010701 | |
| Disease | low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 1.25e-03 | 200 | 8 | 2 | EFO_0004611, EFO_0020945 | |
| Disease | triglycerides:total lipids ratio, high density lipoprotein cholesterol measurement | 1.32e-03 | 206 | 8 | 2 | EFO_0004612, EFO_0020947 | |
| Disease | very low density lipoprotein cholesterol measurement, lipid measurement | 1.50e-03 | 220 | 8 | 2 | EFO_0004529, EFO_0008317 | |
| Disease | Diabetes Mellitus, Non-Insulin-Dependent | 1.52e-03 | 221 | 8 | 2 | C0011860 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesterol:total lipids ratio | 1.53e-03 | 222 | 8 | 2 | EFO_0008317, EFO_0020943 | |
| Disease | triglyceride measurement, very low density lipoprotein cholesterol measurement | 1.56e-03 | 224 | 8 | 2 | EFO_0004530, EFO_0008317 | |
| Disease | triglycerides:total lipids ratio, very low density lipoprotein cholesterol measurement | 1.57e-03 | 225 | 8 | 2 | EFO_0008317, EFO_0020947 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipid measurement | 1.63e-03 | 229 | 8 | 2 | EFO_0004639, EFO_0008317 | |
| Disease | very low density lipoprotein cholesterol measurement, free cholesterol:total lipids ratio | 1.77e-03 | 239 | 8 | 2 | EFO_0008317, EFO_0020945 | |
| Disease | cholesteryl esters:total lipids ratio, high density lipoprotein cholesterol measurement | 1.83e-03 | 243 | 8 | 2 | EFO_0004612, EFO_0020944 | |
| Disease | very low density lipoprotein cholesterol measurement | 2.09e-03 | 260 | 8 | 2 | EFO_0008317 | |
| Disease | very low density lipoprotein cholesterol measurement, cholesteryl esters:total lipids ratio | 2.15e-03 | 264 | 8 | 2 | EFO_0008317, EFO_0020944 | |
| Disease | triglyceride measurement, high density lipoprotein cholesterol measurement | 2.32e-03 | 274 | 8 | 2 | EFO_0004530, EFO_0004612 | |
| Disease | cholesterol:total lipids ratio, high density lipoprotein cholesterol measurement | 2.35e-03 | 276 | 8 | 2 | EFO_0004612, EFO_0020943 | |
| Disease | very low density lipoprotein cholesterol measurement, phospholipids:total lipids ratio | 2.61e-03 | 291 | 8 | 2 | EFO_0008317, EFO_0020946 | |
| Disease | phospholipids:total lipids ratio, high density lipoprotein cholesterol measurement | 2.90e-03 | 307 | 8 | 2 | EFO_0004612, EFO_0020946 | |
| Disease | thyroid stimulating hormone measurement | 3.20e-03 | 323 | 8 | 2 | EFO_0004748 | |
| Disease | 3-hydroxypropylmercapturic acid measurement | 3.79e-03 | 352 | 8 | 2 | EFO_0007014 | |
| Disease | comparative body size at age 10, self-reported | 5.35e-03 | 420 | 8 | 2 | EFO_0009819 | |
| Disease | fatty acid measurement | 5.75e-03 | 436 | 8 | 2 | EFO_0005110 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| QWFHSLQWKKKIYKY | 151 | Q8IY22 | |
| EDQCSYKWWQKYQKR | 216 | Q96SW2 | |
| YKWWQKYQKRKFHCA | 221 | Q96SW2 | |
| WNKIKAWQKIFKHYD | 721 | P20807 | |
| KDAKSYFSQKWKKYW | 581 | Q8WXI2 | |
| WVADQNWIKKYHYHK | 356 | O15374 | |
| DWKKKNKYFWQNFRK | 146 | O94885 | |
| WWNQGKCRKQKHFFY | 166 | Q6PKC3 | |
| DYKKQYEANKAHWKW | 5546 | P20929 |